UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
OR
For the transition period from ____________ to ____________
Commission file number:
ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation of organization)
(Address of principal executive offices) (Zip Code) | (I.R.S. Employer Identification No.)
( (Registrant’s telephone number, including area code:) |
None
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| | | |
| (Title of each class) | (Trading Symbol) | (Name of each exchange on which registered) |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ |
|
| Non-accelerated filer ☐ | Smaller reporting company |
| Emerging Growth Company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of April 25, 2022, the registrant had
ULTRALIFE CORPORATION AND SUBSIDIARIES
INDEX
| Page |
||
| PART I. |
FINANCIAL INFORMATION |
|
| Item 1. |
Consolidated Financial Statements (unaudited): |
|
| Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 |
1 |
|
| Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the Three-Month Periods Ended March 31, 2022 and March 31, 2021 |
2 |
|
| Consolidated Statements of Cash Flows for the Three-Month Periods Ended March 31, 2022 and March 31, 2021 |
3 |
|
| Consolidated Statements of Changes in Shareholders’ Equity for the Three-Month Periods Ended March 31, 2022 and March 31, 2021 |
4 |
|
| Notes to Consolidated Financial Statements |
5 |
|
| Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
17 |
| Item 4. |
Controls and Procedures |
24 |
| PART II. |
OTHER INFORMATION |
|
| Item 6. |
Exhibits |
25 |
| Signatures |
26 |
PART I. FINANCIAL INFORMATION
Item 1. CONSOLIDATED FINANCIAL STATEMENTS
ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In Thousands except share amounts)
(Unaudited)
| March 31, 2022 | December 31, 2021 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Trade accounts receivable, net of allowance for doubtful accounts of $ and $, respectively | ||||||||
| Inventories, net | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Property, plant and equipment, net | ||||||||
| Goodwill | ||||||||
| Other intangible assets, net | ||||||||
| Deferred income taxes, net | ||||||||
| Other noncurrent assets | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Current portion of long-term debt | ||||||||
| Accrued compensation and related benefits | ||||||||
| Accrued expenses and other current liabilities | ||||||||
| Total current liabilities | ||||||||
| Long-term debt | ||||||||
| Deferred income taxes | ||||||||
| Other noncurrent liabilities | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 9) | ||||||||
| Shareholders’ equity: | ||||||||
| Preferred stock – par value $ per share; authorized shares; issued | ||||||||
| Common stock – par value $ per share; authorized shares; issued – shares at March 31, 2022 and shares at December 31, 2021; outstanding – shares at March 31, 2022 and shares at December 31, 2021 | ||||||||
| Capital in excess of par value | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Treasury stock - at cost; shares at March 31, 2022 and shares at December 31, 2021 | ( | ) | ( | ) | ||||
| Total Ultralife Corporation equity | ||||||||
| Non-controlling interest | ||||||||
| Total shareholders’ equity | ||||||||
| Total liabilities and shareholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
| ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF (LOSS) INCOME AND COMPREHENSIVE (LOSS) INCOME (In Thousands except per share amounts) (Unaudited) |
| Three-month period ended | ||||||||
| March 31, 2022 | March 31, 2021 | |||||||
| Revenues | $ | $ | ||||||
| Cost of products sold | ||||||||
| Gross profit | ||||||||
| Operating expenses: | ||||||||
| Research and development | ||||||||
| Selling, general and administrative | ||||||||
| Total operating expenses | ||||||||
| Operating (loss) income | ( | ) | ||||||
| Other (expense) income: | ||||||||
| Interest and financing expense | ( | ) | ( | ) | ||||
| Miscellaneous income | ||||||||
| Total other expense | ( | ) | ( | ) | ||||
| (Loss) income before income taxes | ( | ) | ||||||
| Income tax (benefit) provision | ( | ) | ||||||
| Net (loss) income | ( | ) | ||||||
| Net income attributable to non-controlling interest | ( | ) | ( | ) | ||||
| Net (loss) income attributable to Ultralife Corporation | ( | ) | ||||||
| Other comprehensive (loss) gain: | ||||||||
| Foreign currency translation adjustments | ( | ) | ||||||
| Comprehensive (loss) income attributable to Ultralife Corporation | $ | ( | ) | $ | ||||
| Net (loss) income per share attributable to Ultralife common shareholders – basic | $ | (. | ) | $ | . | |||
| Net (loss) income per share attributable to Ultralife common shareholders – diluted | $ | (. | ) | $ | . | |||
| Weighted average shares outstanding – basic | ||||||||
| Potential common shares | ||||||||
| Weighted average shares outstanding - diluted | ||||||||
The accompanying notes are an integral part of these consolidated financial statements.
| ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in Thousands) (Unaudited) |
| Three-month period ended | ||||||||
| March 31, 2022 | March 31, 2021 | |||||||
| OPERATING ACTIVITIES: | ||||||||
| Net (loss) income | $ | ( | ) | $ | ||||
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ||||||||
| Depreciation | ||||||||
| Amortization of intangible assets | ||||||||
| Amortization of financing fees | ||||||||
| Stock-based compensation | ||||||||
| Deferred income taxes | ( | ) | ||||||
| Proceeds from litigation settlement | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ) | |||||||
| Inventories | ) | |||||||
| Prepaid expenses and other assets | ||||||||
| Accounts payable and other liabilities | ( | ) | ||||||
| Net cash (used in) provided by operating activities | ) | |||||||
| INVESTING ACTIVITIES: | ||||||||
| Purchases of property, plant and equipment | ) | ( | ) | |||||
| Net cash used in investing activities | ) | ( | ) | |||||
| FINANCING ACTIVITIES: | ||||||||
| Borrowings on revolving credit facility | ||||||||
| Payments on term loan facility | ( | ) | ( | ) | ||||
| Proceeds from exercise of stock options | ||||||||
| Tax withholdings on stock-based awards | ( | ) | ( | ) | ||||
| Net cash provided by (used in) financing activities | ( | ) | ||||||
| Effect of exchange rate changes on cash | ||||||||
| (DECREASE) INCREASE IN CASH | ( | ) | ||||||
| Cash, Beginning of period | ||||||||
| Cash, End of period | $ | $ | ||||||
| The accompanying notes are an integral part of these consolidated financial statements. |
| ULTRALIFE CORPORATION AND SUBSIDIARIES |
|||||||||||||||
| CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY |
|||||||||||||||
| (In Thousands except share amounts) (Unaudited) |
| Capital | Accumulated | |||||||||||||||||||||||||||||||
| Common Stock | in Excess | Other | Non- | |||||||||||||||||||||||||||||
| Number of | of Par | Comprehensive | Accumulated | Treasury | Controlling | |||||||||||||||||||||||||||
| Shares | Amount | Value | Income (Loss) | Deficit | Stock | Interest | Total | |||||||||||||||||||||||||
| Balance – December 31, 2020 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||
| Net income | ||||||||||||||||||||||||||||||||
| Stock option exercises | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Stock-based compensation – stock options | ||||||||||||||||||||||||||||||||
| Stock-based compensation – restricted stock | ||||||||||||||||||||||||||||||||
| Vesting of restricted stock | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Foreign currency translation adjustments adjustments | ||||||||||||||||||||||||||||||||
| Balance – March 31, 2021 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||
| Balance – December 31, 2021 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||
| Net (loss) income | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Stock option exercises | ( | ) | ||||||||||||||||||||||||||||||
| Stock-based compensation – stock options | ||||||||||||||||||||||||||||||||
| Stock-based compensation – restricted stock | ||||||||||||||||||||||||||||||||
| Foreign currency translation adjustments adjustments | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance – March 31, 2022 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | |||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
ULTRALIFE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands except share and per share amounts)
(Unaudited)
| 1. | BASIS OF PRESENTATION |
The accompanying unaudited Consolidated Financial Statements of Ultralife Corporation and its subsidiaries (the “Company” or “Ultralife”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and notes for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered necessary for a fair presentation of the Consolidated Financial Statements have been included. Results for interim periods should not be considered indicative of results to be expected for a full year. Reference should be made to the Consolidated Financial Statements and related notes thereto contained in our Form 10-K for the year ended December 31, 2021.
The December 31, 2021 consolidated balance sheet information referenced herein was derived from audited financial statements but does not include all disclosures required by GAAP.
Certain items previously reported in specific financial statement captions have been reclassified to conform to the current presentation.
Recent Accounting Guidance Not Yet Adopted
In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments”, which requires entities to measure all expected credit losses for financial assets held at the reporting data based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This guidance is effective for the Company for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company is currently assessing the impact that adopting this new accounting standard will have on our consolidated financial statements.
| 2. | ACQUISITION |
On December 13, 2021, the Company acquired all the outstanding shares of Excell for an aggregate net purchase price of $
On December 13, 2021, 1336889 B.C. Unlimited Liability Company, a British Columbia unlimited liability company and wholly-owned subsidiary of Ultralife Canada Holding Corp., a Delaware corporation (“UCHC”) and wholly-owned subsidiary of Ultralife Excell Holding Corp., a Delaware corporation (“UEHC”) and wholly-owned subsidiary of Ultralife Corporation, completed the acquisition of all issued and outstanding shares of Excell Battery Canada Inc., a British Columbia corporation (“Excell Canada”) (the “Excell Canada Acquisition”), and, concurrently, 1336902 B.C. Unlimited Liability Company, a British Columbia unlimited liability company and wholly-owned subsidiary of UCHC, completed the acquisition of all issued and outstanding shares of 656700 B.C. LTD, a British Columbia corporation and sole owner of all issued and outstanding shares of Excell Battery Corporation USA, a Texas corporation (“Excell USA”, and together with Excell Canada, “Excell Battery Group” or “Excell”) (the “Excell USA Acquisition”, and together with the Excell Canada Acquisition, the “Excell Acquisition”).
Based in Canada with U.S. operations, Excell is a leading independent designer and manufacturer of high-performance smart battery systems, battery packs and monitoring systems to customer specifications. Excell serves a variety of industrial markets including downhole drilling, OEM industrial and medical devices, automated meter reading, ruggedized computers, and mining, marine and other mission critical applications which demand uncompromised safety, service, reliability and quality.
The Excell Canada Acquisition was completed pursuant to a Share Purchase Agreement dated December 13, 2021 (the “Excell Canada Acquisition Agreement”) by and among 1336889 B.C. Unlimited Liability Company, Mark Kroeker, Randolph Peters, Brian Larsen, M. & W. Holdings Ltd., Karen Kroeker, Heather Peterson, Michael Kroeker, Nicholas Kroeker, Brentley Peters, Craig Peters, Kurtis Peters, Heather Larsen, Ian Kane, Carol Peters, and 0835205 B.C. LTD (the “Excell Canada Sellers”), Mark Kroeker in his capacity as the Excell Canada Sellers’ Representative, and Excell Canada. The Excell USA Acquisition was completed pursuant to a Share Purchase Agreement dated December 13, 2021 (the “Excell USA Acquisition Agreement”, and together with the Excell Canada Acquisition Agreement, the “Excell Acquisition Agreements”) by and among 1336902 B.C. Unlimited Liability Company, M. & W. Holdings Ltd., Ian Kane, Sanford Capital Ltd., Arcee Enterprises Inc., and 0835205 B.C. Ltd. (the “Excell USA Sellers”, and together with the Excell Canada Sellers, the “Sellers”), Mark Kroeker in his capacity as the Excell USA Sellers’ Representative, and 656700 B.C. LTD. The Excell Acquisition Agreements contain customary terms and conditions including representations, warranties and indemnification provisions. A portion of the consideration paid to the Sellers is being held in escrow for indemnification purposes for a period of twelve months from the closing date.
The Excell Acquisition was funded by the Company through a combination of cash on hand and borrowings under the Amended Credit Facilities (Note 3).
The Excell Acquisition was accounted for in accordance with the accounting treatment of a business combination pursuant to FASB ASC Topic 805, Business Combinations (“ASC 805”). Accordingly, the purchase price was allocated to the tangible and intangible assets acquired and the liabilities assumed based on their estimated fair values on the acquisition date. The excess of the purchase price over the estimated fair value of the separately identifiable assets acquired and liabilities assumed was allocated to goodwill. Management is responsible for determining the acquisition date fair value of the assets acquired and liabilities assumed, which requires the use of various assumptions and judgments that are inherently subjective. The purchase price allocation presented below reflects all known information about the fair value of the assets acquired and liabilities assumed as of the acquisition date. The purchase price allocation is subject to change should additional information existing as of the acquisition date about the fair value of the assets acquired and liabilities assumed becomes known. The final purchase price allocation may reflect material changes in the valuation of assets acquired and liabilities assumed, including but not limited to intangible assets, fixed assets, deferred taxes, and residual goodwill.
| Cash | $ | |||
| Accounts receivable | ||||
| Inventories | ||||
| Prepaid expenses and other current assets | ||||
| Property, plant and equipment | ||||
| Goodwill | ||||
| Other intangible assets | ||||
| Other noncurrent assets | ||||
| Accounts payable | ( | ) | ||
| Accrued compensation and related benefits | ( | ) | ||
| Accrued expenses and other current liabilities | ( | ) | ||
| Deferred tax liability, net | ( | ) | ||
| Other noncurrent liabilities | ( | ) | ||
| Net assets acquired | $ |
The purchase price allocation was adjusted during the three-month period ended March 31, 2022 to reflect a change in the estimated fair value of certain other intangible assets acquired. The measurement period adjustment resulted in a $
The goodwill included in the Company’s purchase price allocation presented above represents the value of Excell’s assembled and trained workforce, the incremental value that Excell engineering and technology will bring to the Company and the revenue growth which is expected to occur over time which is attributable to increased market penetration from future new products and customers. The goodwill acquired in connection with the acquisition is not deductible for income tax purposes.
Other intangible assets were valued using the income approach which requires a forecast of all expected future cash flows and the use of certain assumptions and estimates. The following table summarizes the estimated fair value and annual amortization for each of the identifiable intangible assets acquired.
| Annual Amortization | ||||||||||||||||||||||||||||
| Estimated Fair Value | Amortization Period (Years) | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | ||||||||||||||||||||||
| Customer relationships | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||
| Trade name | Indefinite | - | - | - | - | - | ||||||||||||||||||||||
| Customer contracts | ||||||||||||||||||||||||||||
| Backlog | ||||||||||||||||||||||||||||
| Technology | ||||||||||||||||||||||||||||
| Total | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||
We acquired right-of-use assets and assumed lease liabilities of $
The operating results and cash flows of Excell are reflected in the Company’s consolidated financial statements from the date of acquisition. Excell is included in the Battery & Energy Products segment.
For the three months ended March 31, 2022, Excell contributed revenue of $
| 3. | DEBT |
On December 13, 2021, Ultralife, Southwest Electronic Energy Corporation, a Texas corporation (“SWE”), CLB, INC., a Texas corporation and wholly owned subsidiary of SWE (“CLB”), UEHC, UCHC and Excell USA, as borrowers, entered into the Second Amendment Agreement with KeyBank National Association (“KeyBank” or the “Bank”), as lender and administrative agent, to amend the Credit and Security Agreement dated May 31, 2017 as amended by the First Amendment Agreement by and among Ultralife, SWE, CLB and KeyBank dated May 1, 2019 (the “Credit Agreement”, and together with the Second Amendment Agreement, the “Amended Credit Agreement”).
The Amended Credit Agreement, among other things, provides for a -year, $
Upon closing of the Excell Acquisition on December 13, 2021, the Company drew down the full amount of the Term Loan Facility and $
The remaining availability under the Revolving Credit Facility is subject to certain borrowing base limits based on trade receivables and inventories.
The Company is required to repay the borrowings under the Term Loan Facility in equal consecutive monthly payments commencing on February 1, 2022, in arrears, together with applicable interest. All unpaid principal and accrued and unpaid interest with respect to the Term Loan Facility is due and payable in full on January 1, 2027. All unpaid principal and accrued and unpaid interest with respect to the Revolving Credit Facility is due and payable in full on May 30, 2025. The Company may voluntarily prepay principal amounts outstanding at any time subject to certain restrictions.
In addition to the customary affirmative and negative covenants, the Company must maintain a consolidated senior leverage ratio, as defined in the Amended Credit Agreement, of equal to or less than
Borrowings under the Amended Credit Facilities are secured by substantially all the assets of the Company and its subsidiaries.
Interest will accrue on outstanding indebtedness under the Amended Credit Facilities at the Base Rate or the Overnight LIBOR Rate, as selected by the Company, plus the applicable margin. The Base Rate is the higher of (a) the Prime Rate, (b) the Federal Funds Effective Rate plus
The Company must pay a fee of
Payments must be made by the Company to the extent borrowings exceed the maximum amount then permitted to be drawn on the Amended Credit Facilities and from the proceeds of certain transactions. Upon the occurrence of an event of default, the outstanding obligations may be accelerated, and the Bank will have other customary remedies including resort to the security interest the Company provided to the Bank.
| 4. |
EARNINGS PER SHARE |
Basic earnings (loss) per share (“EPS”) is computed by dividing net income (loss) attributable to Ultralife by the weighted average shares outstanding during the period. Diluted EPS includes the dilutive effect of securities, if any, and is calculated using the treasury stock method. For the three-month period ended March 31, 2022, there were no outstanding awards included in the calculation of diluted weighted average shares outstanding and
| 5. |
SUPPLEMENTAL BALANCE SHEET INFORMATION |
Fair Value Measurements and Disclosures
The fair value of financial instruments approximated their carrying values at March 31, 2022 and December 31, 2021. The fair value of cash, accounts receivable, accounts payable, accrued liabilities, and the current portion of long-term debt approximates carrying value due to the short-term nature of these instruments.
Cash
The composition of the Company’s cash was as follows:
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Cash | $ | $ | ||||||
| Restricted cash | ||||||||
| Total | $ | $ | ||||||
As of March 31, 2022 and December 31, 2021, restricted cash included $
Inventories, Net
Inventories are stated at the lower of cost or net realizable value, net of obsolescence reserves, with cost determined under the first-in, first-out (FIFO) method. The composition of inventories, net was:
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Raw materials | $ | $ | ||||||
| Work in process | ||||||||
| Finished goods | ||||||||
| Total | $ | $ | ||||||
Property, Plant and Equipment, Net
Major classes of property, plant and equipment consisted of the following:
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Land | $ | $ | ||||||
| Buildings and leasehold improvements | ||||||||
| Machinery and equipment | ||||||||
| Furniture and fixtures | ||||||||
| Computer hardware and software | ||||||||
| Construction in process | ||||||||
| Less: Accumulated depreciation | ( | ) | ( | ) | ||||
| Property, plant and equipment, net | $ | $ | ||||||
Depreciation expense for property, plant and equipment was $
Goodwill
The following table summarizes the goodwill activity by segment for the three-month period ended March 31, 2022.
| Battery & Energy | Communications | |||||||||||
| Products | Systems | Total | ||||||||||
| Balance – December 31, 2021 | $ | $ | $ | |||||||||
| Measurement period adjustment (1) | ( | ) | ( | ) | ||||||||
| Effect of foreign currency translation | ( | ) | ( | ) | ||||||||
| Balance – March 31, 2022 | $ | $ | $ | |||||||||
| (1) |
Change for measurement period adjustment related to Excell Acquisition (Note 2). |
Other Intangible Assets, Net
The composition of other intangible assets was:
| at March 31, 2022 | ||||||||||||
| Accumulated | ||||||||||||
| Cost | Amortization | Net | ||||||||||
| Customer relationships | $ | $ | $ | |||||||||
| Patents and technology | ||||||||||||
| Trade names | ||||||||||||
| Trademarks | ||||||||||||
| Other | ||||||||||||
| Total other intangible assets | $ | $ | $ | |||||||||
| at December 31, 2021 |
||||||||||||
| Accumulated |
||||||||||||
| Cost |
Amortization |
Net |
||||||||||
| Customer relationships |
$ | $ | $ | |||||||||
| Patents and technology |
||||||||||||
| Trade names |
||||||||||||
| Trademarks |
||||||||||||
| Other |
||||||||||||
| Total other intangible assets |
$ | $ | $ | |||||||||
The change in the cost of total intangible assets from December 31, 2021 to March 31, 2022 is a result of measurement period adjustment for the Excell Acquisition (Note 2) and the effect of foreign currency translations.
Amortization expense for intangible assets was $
| 6. |
STOCK-BASED COMPENSATION |
We recorded non-cash stock compensation expense in each period as follows:
| Three-month period ended | ||||||||
| March 31, | March 31, | |||||||
| 2022 | 2021 | |||||||
| Stock options | $ | $ | ||||||
| Restricted stock grants | ||||||||
| Total | $ | $ | ||||||
We have stock options outstanding from various stock-based employee compensation plans for which we record compensation cost relating to share-based payment transactions in our financial statements. As of March 31, 2022, there was $
The following table summarizes stock option activity for the three-month period ended March 31, 2022:
| Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (years) | Aggregate Intrinsic Value | |||||||||||||
| Outstanding at January 1, 2022 | $ | |||||||||||||||
| Granted | ||||||||||||||||
| Exercised | ( | ) | ||||||||||||||
| Forfeited or expired | ( | ) | ||||||||||||||
| Outstanding at March 31, 2022 | $ | $ | ||||||||||||||
| Vested and expected to vest at March 31, 2022 | $ | $ | ||||||||||||||
| Exercisable at March 31, 2022 | $ | $ | ||||||||||||||
Cash received from stock option exercises under our stock-based compensation plans for the three-month periods ended March 31, 2022 and March 31, 2021 was $
In October 2020,
| 7. | INCOME TAXES |
Our effective tax rate for the three-month periods ended March 31, 2022 and March 31, 2021 was (
As of December 31, 2021, we have domestic net operating loss (“NOL”) carryforwards of $
As of March 31, 2022, for certain past operations in the U.K., we continue to report a valuation allowance for NOL carryforwards of approximately $
As of March 31, 2022, we have recognized a valuation allowance against our other foreign deferred tax assets, as realization is considered to be more likely than not.
As of March 31, 2022, the Company maintains its assertion that all foreign earnings will be indefinitely reinvested in those operations, other than earnings generated in the U.K.
There were
As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. In August 2020, the Internal Revenue Service (“IRS”) completed its examination of the Company’s federal tax returns for 2016-2018 with no material adjustments identified. Our U.S. tax matters for 2019-2021 remain subject to IRS examination. Our U.S. tax matters for 2005-2007 and 2011-2015 also remain subject to IRS examination due to the remaining availability of NOL carryforwards generated in those years. Our U.S. tax matters for 2005-2007 and 2011-2021 remain subject to examination by various state and local tax jurisdictions. Our tax matters for the years through 2021 remain subject to examination by the respective foreign tax jurisdiction authorities.
| 8. |
OPERATING LEASES |
The Company has operating leases predominantly for operating facilities. As of March 31, 2022, the remaining lease terms on our operating leases range from approximately one (
The components of lease expense for the current and prior-year comparative periods were as follows:
| Three-month period ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Operating lease cost | $ | $ | ||||||
| Variable lease cost | ||||||||
| Total lease cost | $ | $ | ||||||
Supplemental cash flow information related to leases was as follows:
| Three-month period ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Cash paid for amounts included in the measurement of lease liabilities: | ||||||||
| Operating cash flows from operating leases | $ | $ | ||||||
| Right-of-use assets obtained in exchange for lease liabilities: | $ | $ | ||||||
Supplemental consolidated balance sheet information related to leases was as follows:
| Balance sheet classification |
March 31, 2022 |
December 31, 2021 |
|||||||
| Assets: |
|||||||||
| Operating lease right-of-use asset |
Other noncurrent assets |
$ | $ | ||||||
| Liabilities: |
|||||||||
| Current operating lease liability |
Accrued expenses and other current liabilities |
$ | $ | ||||||
| Operating lease liability, net of current portion |
Other noncurrent liabilities |
||||||||
| Total operating lease liability |
$ | $ | |||||||
| Weighted-average remaining lease term (years) |
|||||||||
| Weighted-average discount rate |
% | % | |||||||
Future minimum lease payments as of March 31, 2022 are as follows:
| Maturity of operating lease liabilities |
||||
| 2022 |
$ | |||
| 2023 |
||||
| 2024 |
||||
| 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| Thereafter |
||||
| Total lease payments |
||||
| Less: Imputed interest |
( |
) | ||
| Present value of remaining lease payments |
$ |
| 9. |
COMMITMENTS AND CONTINGENCIES |
Purchase Commitments
As of March 31, 2022, we have made commitments to purchase approximately $
Product Warranties
We estimate future warranty costs to be incurred for product failure rates, material usage and service costs in the development of our warranty obligations. Estimated future costs are based on actual past experience and are generally estimated as a percentage of sales over the warranty period. Changes in our product warranty liability during the first three months of 2022 and 2021 were as follows:
| Three-month period ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Accrued warranty obligations – beginning | $ | $ | ||||||
| Accruals for warranties issued | ||||||||
| Settlements made | ( | ) | ( | ) | ||||
| Accrued warranty obligations – ending | $ | $ | ||||||
Contingencies and Legal Matters
We are subject to legal proceedings and claims that arise from time to time in the normal course of business. We believe that the final disposition of any such matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, recognizing that legal matters are subject to inherent uncertainties, there exists the possibility that ultimate resolution of these matters could have a material adverse impact on the Company’s financial position, results of operations or cash flows. We are not aware of any such situations at this time.
| 10. |
REVENUE RECOGNITION |
Revenues are generated from the sale of products. Performance obligations are met and revenue is recognized upon transfer of control to the customer, which is generally upon shipment. When contract terms require transfer of control upon delivery at a customer’s location, revenue is recognized on the date of delivery. For products shipped under vendor managed inventory arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company. Revenue is measured as the amount of consideration we expect to receive in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return.
Revenues recognized from prior period performance obligations for the three-month periods ended March 31, 2022 and 2021 were not material.
Deferred revenue, unbilled revenue and deferred contract costs recorded on our consolidated balance sheets as of March 31, 2022 and December 31, 2021 were not material. As of March 31, 2022 and December 31, 2021, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, we have applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.
| 11. |
BUSINESS SEGMENT INFORMATION |
We report our results in
Three-month period ended March 31, 2022:
|
| Battery & Energy Products | Communications Systems | Corporate | Total | ||||||||||||
| Revenues | $ | $ | $ | - | $ | |||||||||||
| Segment contribution | ( | ) | ( | ) | ||||||||||||
| Other expense | ( | ) | ( | ) | ||||||||||||
| Tax benefit | ||||||||||||||||
| Non-controlling interest | ( | ) | ( | ) | ||||||||||||
| Net loss attributable to Ultralife | $ | ( | ) | |||||||||||||
Three-month period ended March 31, 2021:
| Battery & Energy Products | Communications Systems | Corporate | Total | |||||||||||||
| Revenues | $ | $ | $ | - | $ | |||||||||||
| Segment contribution | ( | ) | ||||||||||||||
| Other expense | ( | ) | ( | ) | ||||||||||||
| Tax provision | ( | ) | ( | ) | ||||||||||||
| Non-controlling interest | ( | ) | ( | ) | ||||||||||||
| Net income attributable to Ultralife | $ | |||||||||||||||
The following tables disaggregate our business segment revenues by major source and geography.
Commercial and Government/Defense Revenue Information:
Three-month period ended March 31, 2022:
| Total Revenue | Commercial | Government/ Defense | ||||||||||
| Battery & Energy Products | $ | $ | $ | |||||||||
| Communications Systems | ||||||||||||
| Total | $ | $ | $ | |||||||||
| % | % | |||||||||||
Three-month period ended March 31, 2021:
| Total Revenue |
Commercial |
Government/ Defense |
||||||||||
| Battery & Energy Products |
$ | $ | $ | |||||||||
| Communications Systems |
||||||||||||
| Total |
$ | $ | $ | |||||||||
| % | % | |||||||||||
U.S. and Non-U.S. Revenue Information1:
Three-month period ended March 31, 2022:
| Total Revenue |
United States |
Non-United States |
||||||||||
| Battery & Energy Products |
$ | $ | $ | |||||||||
| Communications Systems |
||||||||||||
| Total |
$ | $ | $ | |||||||||
| % | % | |||||||||||
Three-month period ended March 31, 2021:
| Total Revenue |
United States |
Non-United States |
||||||||||
| Battery & Energy Products |
$ | $ | $ | |||||||||
| Communications Systems |
||||||||||||
| Total |
$ | $ | $ | |||||||||
| % | % | |||||||||||
1 Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. This report contains certain forward-looking statements and information that are based on the beliefs of management as well as assumptions made by and information currently available to management. The statements contained in this report relating to matters that are not historical facts are forward-looking statements that involve risks and uncertainties, including, but not limited to, the continued impact of COVID-19 and the related supply chain disruptions on our business, operating results and financial condition; our reliance on certain key customers; reduced U.S. and foreign military spending including the uncertainty associated with government budget approvals; our efforts to develop new commercial applications for our products; fluctuations in the price of oil and the resulting impact on the demand for downhole drilling; the unique risks associated with our China operations; potential disruptions in our supply of raw materials and components; our ability to retain top management and key personnel; possible breaches in information systems security and other disruptions in our information technology systems; our resources being overwhelmed by our growth; possible future declines in demand for the products that use our batteries or communications systems; potential costs attributable to the warranties we supply with our products and services; safety risks, including the risk of fire; variability in our quarterly and annual results and the price of our common stock; our entrance into new end-markets which could lead to additional financial exposure; our inability to comply with changes to the regulations for the shipment of our products; our customers’ demand falling short of volume expectations in our supply agreements; our exposure to foreign currency fluctuations; negative publicity concerning Lithium-ion batteries; possible impairments of our goodwill and other intangible assets; our ability to utilize our net operating loss carryforwards; the risk that we are unable to protect our proprietary and intellectual property; rules and procedures regarding contracting with the U.S. and foreign governments; exposure to possible violations of the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act or other anti-corruption laws; known and unknown environmental matters; possible audits of our contracts by the U.S. and foreign governments and their respective defense agencies; our ability to comply with government regulations regarding the use of “conflict minerals”; technological innovations in the non-rechargeable and rechargeable battery industries; and other risks and uncertainties, certain of which are beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those forward-looking statements described herein. When used in this report, the words “anticipate,” “believe,” “estimate,” “expect,” “seek,” “project,” “intend,” “plan,” “may,” “will,” “should,” or words of similar import are intended to identify forward-looking statements. For further discussion of certain of the matters described above and other risks and uncertainties, see Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021.
Although we base these forward-looking statements on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industries in which we operate may differ materially from those made in or suggested by the forward-looking statements contained herein. In addition, even if our results of operations, financial condition and liquidity and the development of the industries in which we operate are consistent with the forward-looking statements contained in this quarterly report, those results or developments may not be indicative of results or developments in subsequent periods. Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.
Undue reliance should not be placed on our forward-looking statements. Except as required by law, we disclaim any obligation to update any risk factors or to publicly announce the results of any revisions to any of the forward-looking statements contained in this Form 10-Q or our Annual Report on Form 10-K for the year ended December 31, 2021 to reflect new information or risks, future events or other developments.
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the consolidated financial statements and notes thereto in Part I, Item 1 of this Form 10-Q, and the consolidated financial statements and notes thereto and risk factors in our Annual Report on Form 10-K for the year ended December 31, 2021.
The financial information in this MD&A is presented in thousands of dollars, except for share and per share amounts, unless otherwise specified.
General
We offer products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government, defense and commercial sectors. With an emphasis on strong engineering and a collaborative approach to problem solving, we design and manufacture power and communications systems including: rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom engineered systems related to those product lines. We continually evaluate ways to grow, including the design, development and sale of new products, expansion of our sales force to penetrate new markets and territories, as well as seeking opportunities to expand through acquisitions.
We sell our products worldwide through a variety of trade channels, including original equipment manufacturers (“OEMs”), industrial and defense supply distributors, and directly to U.S. and foreign defense departments. We enjoy strong name recognition in our markets under our Ultralife® Batteries, Lithium Power®, McDowell Research®, AMTI™, ABLE™, ACCUTRONICS™, ACCUPRO™, ENTELLION™, SWE Southwest Electronic Energy Group™, SWE DRILL-DATA™, SWE SEASAFE™, Excell Battery Group and Criterion Gauge brands. We have sales, operations and product development facilities in North America, Europe and Asia.
We report our results in two operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes: Lithium 9-volt, cylindrical, thin cell and other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes: RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that reporting performance at the gross profit level is the best indicator of segment performance. As such, we report segment performance at the gross profit level and operating expenses as Corporate charges. See Note 11 to the consolidated financial statements of this Form 10-Q.
Our website address is www.ultralifecorporation.com. We make available free of charge via a hyperlink on our website (see Investor Relations link on the website) our annual reports on Form 10-K, proxy statements, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports and statements as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (“SEC”). We will provide copies of these reports upon written request to the attention of Philip A. Fain, CFO, Treasurer and Secretary, Ultralife Corporation, 2000 Technology Parkway, Newark, New York, 14513. Our filings with the SEC are also available through the SEC website at www.sec.gov or at the SEC Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 or by calling 1-800-SEC-0330.
COVID-19
The COVID-19 pandemic has created significant economic disruption and uncertainty around the world. The Company continues to closely monitor the developments surrounding COVID-19 and take actions to mitigate the business risks involved. During this challenging time, we remain focused on ensuring the health and safety of our employees by implementing the protocols established by public health officials and meeting the demand of our customers. While we have maintained normal business operations at all our facilities with the exception of the well-publicized shutdowns in China which impacted our Shenzhen facility in the first quarter of 2022, the supply chain disruptions including increased lead times on key components experienced within our business and by our customers, impacted our work schedules and timing of shipments. The continuing impact of these conditions on our business is uncertain and will depend on many evolving factors which we continue to monitor but cannot predict, including the duration and scope of the pandemic and its variants, resulting actions taken by governments, businesses and individuals, and the flow-through impact on operations and supply chains. Potential effects of COVID-19 that may continue to adversely impact our future business include limited availability and/or increased cost of raw materials and components used in our products, reduced demand and/or pricing for our products, inability of our customers to pay for our products or remain solvent, and reduced availability of our workforce. Prolonged adverse effects of COVID-19 on our business could result in the impairment of long-lived assets including goodwill and other intangible assets. Further, we cannot predict all possible adverse effects the COVID-19 pandemic may cause. Consequently, there may be adverse effects in addition to those described above. We will continue to closely monitor the developments surrounding COVID-19 and take actions when possible to mitigate the business risks involved and the potential effects of COVID-19 on our business.
Overview
Consolidated revenues of $30,373 for the three-month period ended March 31, 2022, increased by $4,400 or 16.9%, over $25,973 for the three-month period ended March 31, 2021, reflecting our December 13, 2021 acquisition of Excell Battery Group (“Excell”) and increased sales in our medical, oil & gas and industrial battery markets, partially offset by lower revenues for government/defense which continued to be impacted by supply chain challenges. Excluding Excell, commercial revenues of $16,824 for the quarter-ended March 31, 2022 increased $2,479 or 17.3% over the year-earlier period, and government/defense revenues of $7,113 decreased $4,515 or 38.8% from the 2021 period.
Gross profit was $6,958, or 22.9% of revenue, for the three-month period ended March 31, 2022, compared to $6,978, or 26.9% of revenue, for the same quarter a year ago. The 400-basis point decline primarily reflects the lower sales volume for Communications Systems resulting in lower factory throughput and incremental costs in 2022 associated with supply chain disruptions, including rapid increases in the cost of some key components in advance of price realization from customers, and the transition of a multitude of new products to higher volume production.
Operating expenses increased to $7,253 for the three-month period ended March 31, 2022, compared to $6,026 for the three-month period ended March 31, 2021. The increase of $1,227 or 20.4% was primarily attributable to our acquisition of Excell which contributed operating expenses of $1,058. Excluding Excell, operating expenses increased by $169 or 2.8% reflecting our continued investment in new product development, including approximately $360 for engineering resources and test materials dedicated to the May 2021 indefinite-delivery/indefinite-quantity contract form the U.S. Army for purchases of Conformal Wear Batteries not to exceed $168,000 during the three-year base award period with the potential for up to an additional $350,000 should the six one-year options be exercised. Operating expenses as a percentage of sales increased 70 basis points from 23.2% for the first quarter of 2021 to 23.9% for the current quarter.
Operating loss for the three-month period ended March 31, 2022 was ($295), or (1.0%) of revenues, compared to operating income of $952, or 3.7% of revenues, for the year-earlier period. The decrease in operating income primarily resulted from lower sales for our Communications Systems segment, a reduction in gross margin due to supply chain disruptions, including rapid increases in the cost of some key components in advance of price realization from customers, and the transition of new products to high volume manufacturing, higher new product development costs to support our organic growth initiatives, and $125 of acquisition accounting adjustments and one-time expenses related to the acquisition of Excell.
Net loss attributable to Ultralife was ($168), or ($0.01) per share – basic and diluted, for the three-month period ended March 31, 2022, compared to net income attributable to Ultralife of $671, or $0.04 per share – basic and diluted, for the three-month period ended March 31, 2021.
Adjusted EBITDA, defined as net (loss) income attributable to Ultralife before net interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expenses/income that we do not consider reflective of our ongoing operations, amounted to $1,103, or 3.6% of revenues, for the first quarter of 2022, compared to $2,012, or 7.8% of revenues, for the first quarter of 2021. See the section “Adjusted EBITDA” beginning on Page 21 for a reconciliation of Adjusted EBITDA to net income attributable to Ultralife.
Looking forward, as we balance the impact of current supply chain disruptions, we continue to advance new product development initiatives, receive early acceptance of our new product rollouts, and transition new products to production, thereby retaining the view that our long-term profitable growth drivers, strategy, and expectations remain sound and achievable.
Results of Operations
Three-Month Periods Ended March 31, 2022 and March 31, 2021
Revenues. Consolidated revenues for the three-month period ended March 31, 2022 were $30,373, an increase of $4,400, or 16.9%, over $25,973 for the three-month period ended March 31, 2021. Overall, commercial sales increased 62.1% while government/defense sales decreased 38.8% from the 2021 period. Revenues for the 2022 period include Excell which was acquired by the Company on December 13, 2021.
Battery & Energy Products revenues increased $7,039, or 31.8%, from $22,111 for the three-month period ended March 31, 2021 to $29,150 for the three-month period ended March 31, 2022. The increase was attributable to the $6,436 revenue contribution from the acquisition of Excell, and a 17.3% increase in commercial sales excluding Excell, partially offset by a 24.2% reduction in government/defense sales. The increase in commercial sales, excluding Excell, was driven by a 30.5% increase in industrial market sales including our new Thionyl Chloride and thin cell battery cells, a 20.0% increase in oil & gas market sales reflecting the recent rebound in the energy sector, and a 8.4% increase in medical battery sales due to the high demand for our batteries used in ventilators, respirators, infusion pumps and other medical devices. The decline in government/defense sales was primarily due to supply chain disruptions experienced by our customers which pushed out sales to future periods.
Communications Systems revenues decreased $2,639, or 68.3%, from $3,862 for the three-month period ended March 31, 2021 to $1,223 for the three-month period ended March 31, 2022. This decrease is primarily attributable to supply chain disruptions including extended lead times for components and the push out of certain orders by our customers which delayed approximately $1,600 of sales to future periods and the placement and fulfillment of an order from an international defense contractor in the first quarter of 2021 which is not expected to reoccur until later in 2022.
Cost of Products Sold / Gross Profit. Cost of products sold totaled $23,415 for the quarter ended March 31, 2022, an increase of $4,420, or 23.3%, from the $18,995 reported for the same three-month period a year ago. Consolidated cost of products sold as a percentage of total revenue increased from 73.1% for the three-month period ended March 31, 2021 to 77.1% for the three-month period ended March 31, 2022. Correspondingly, consolidated gross margin decreased from 26.9% for the three-month period ended March 31, 2021, to 22.9% for the three-month period ended March 31, 2022, primarily reflecting lower factory volume for our Communications Systems segment, incremental costs in 2022 associated with supply chain disruptions, including rapid increases in the cost of some key components in advance of price realization from customers, and the transition of a multitude of new products to higher volume production.
For our Battery & Energy Products segment, gross profit for the first quarter of 2022 was $6,721, an increase of $1,285 or 23.6% over gross profit of $5,436 for the first quarter of 2021. Battery & Energy Products’ gross margin of 23.1% decreased by 150 basis points from the 24.6% gross margin for the year-earlier period, reflecting sales mix, incremental costs associated with the transition of new products to higher volume production and higher materials and logistics costs on incoming materials in advance of price realization from customers.
For our Communications Systems segment, gross profit for the first quarter of 2022 was $237 or 19.4% of revenues, compared to gross profit of $1,542 or 39.9% of revenues, for the first quarter of 2021. The decline was primarily due to lower factory volume resulting in the under-absorption of factory costs and unfavorable sales mix.
Operating Expenses. Operating expenses for the three-month period ended March 31, 2022 were $7,253, an increase of $1,227 or 20.4% from the $6,026 for the three-month period ended March 31, 2021. The increase is primarily attributable to the acquisition of Excell, which contributed operating expenses of $1,058 in the first quarter, including $182 of intangible asset amortization. Excluding Excell, operating expenses increased $169 or 2.8% due to our continued investment in new product development, including approximately $360 for engineering resources and test materials dedicated to the May 2021 indefinite-delivery/indefinite-quantity contract from the U.S. Army for purchases of Conformal Wear Batteries not to exceed $168,000 during the three-year base award period with the potential for up to an additional $350,000 should the six one-year options be exercised. Both periods reflected continued tight control over discretionary spending.
Overall, operating expenses as a percentage of revenues were 23.9% for the quarter ended March 31, 2022 compared to 23.2% for the quarter ended March 31, 2021. Amortization expense associated with intangible assets related to our acquisitions was $328 for the first quarter of 2022 ($302 in selling, general and administrative expenses and $26 in research and development costs), compared with $154 for the first quarter of 2021 ($121 in selling, general, and administrative expenses and $33 in research and development costs). Research and development costs were $1,857 for the three-month period ended March 31, 2022, an increase of $210 or 12.8%, from $1,647 for the three-months ended March 31, 2021. The increase is largely attributable to the hiring of engineering resources and the purchase of test materials to support new product development in our Battery & Energy Products business, including those resources and materials dedicated to our Conformal Wearable Battery contract. Selling, general, and administrative expenses increased $1,017 or 23.2%, to $5,396 for the first quarter of 2022 from $4,379 for the first quarter of 2021. The increase is largely attributable to the December 2021 acquisition of Excell which contributed $985 of selling, general and administrative expenses, including intangible asset amortization of $182, for the first quarter of 2022. The remainder includes $70 of one-time non-recurring costs resulting from the acquisition of Excell.
Other Expense. Other expense totaled $117 for the three-month period ended March 31, 2022 compared to $56 for the three-month period ended March 31, 2021. Interest and financing expense, net of interest income, increased $78, or 139.3%, from $56 for the first quarter of 2021 to $134 for the comparable period in 2022. The increase is due to the financing of the Excell acquisition. Miscellaneous income, which primarily represents gains and losses on foreign currency transactions, amounted to $17 for the first quarter of 2022 compared with $0 for the first quarter of 2021, which primarily reflects the translation of U.S.-denominated transactions and balances of Accutronics (U.K.) for the respective periods. The U.S. dollar strengthened against the Pound Sterling by 1.5% during the 2022 first quarter, whereas the U.S. dollar weakened against the Pound Sterling by 0.9% during the 2021 first quarter.
Income Taxes. For the three-month period ended March 31, 2022, Ultralife recognized an income tax benefit of $251, comprised of a current provision of $151 and deferred benefit of $402, compared to a provision of $217 ($49 current, $168 deferred) for the three-month period ended March 31, 2021. Our effective tax rate was 60.9% for the first quarter of 2022 as compared to 24.2% for the first quarter of 2021, primarily attributable to the geographic mix of our operating results, including income taxes incurred on our Excell Canada results, and the larger impact of permanent and discrete adjustments on a smaller amount of pretax loss. See Note 7 to the consolidated financial statements in Item 1 of Part I of this Form 10-Q for additional information regarding our income taxes.
Net (Loss) Income Attributable to Ultralife. Net loss attributable to Ultralife was ($168), or ($0.01) per share – basic and diluted, for the three-month period ended March 31, 2022, compared to net income of $671, or $0.04 per share – basic and diluted, for the three-month period ended March 31, 2021. Weighted average shares outstanding used to compute diluted earnings per share decreased from 16,152,160 for the first quarter of 2021 to 16,103,599 for the first quarter of 2022. The decrease is attributable to there being no dilutive effect of outstanding stock awards for the first quarter of 2022 due to the net loss recognized for the period, as compared to the inclusion of 178,781 potential shares in the computation of diluted EPS for the first quarter of 2021, partially offset by the effect of stock option exercises since the first quarter of 2021.
Adjusted EBITDA
In evaluating our business, we consider and use Adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance. We define Adjusted EBITDA as net income (loss) attributable to Ultralife before interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We also use Adjusted EBITDA as a supplemental measure to review and assess our operating performance and to enhance comparability between periods. We believe the use of Adjusted EBITDA facilitates investors’ understanding of operating performance from period to period by backing out potential differences caused by variations in such items as capital structures (affecting relative interest expense and stock-based compensation expense), the amortization of intangible assets acquired through our business acquisitions (affecting relative amortization expense and provision (benefit) for income taxes), the age and book value of facilities and equipment (affecting relative depreciation expense) and one-time charges/benefits relating to income taxes. We also present Adjusted EBITDA from operations because we believe it is frequently used by securities analysts, investors and other interested parties as a measure of financial performance. We reconcile Adjusted EBITDA to net income (loss) attributable to Ultralife, the most comparable financial measure under GAAP.
We use Adjusted EBITDA in our decision-making processes relating to the operation of our business together with GAAP financial measures such as operating income (loss). We believe that Adjusted EBITDA permits a comparative assessment of our operating performance, relative to our performance based on our GAAP results, while isolating the effects of depreciation and amortization, which may vary from period to period without any correlation to underlying operating performance, and of stock-based compensation, which is a non-cash expense that varies widely among companies. We believe that by presenting Adjusted EBITDA, we assist investors in gaining a better understanding of our business on a going forward basis. We provide information relating to our Adjusted EBITDA so that securities analysts, investors and other interested parties have the same data that we employ in assessing our overall operations. We believe that trends in our Adjusted EBITDA are a valuable indicator of our operating performance on a consolidated basis and of our ability to produce operating cash flows to fund working capital needs, to service debt obligations and to fund capital expenditures.
The term Adjusted EBITDA is not defined under GAAP, and is not a measure of operating income (loss), operating performance or liquidity presented in accordance with GAAP. Our Adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, Adjusted EBITDA should not be considered in isolation or as a substitute for net income (loss) attributable to Ultralife or other consolidated statement of operations data prepared in accordance with GAAP. Some of these limitations include, but are not limited to, the following:
| ● |
Adjusted EBITDA does not reflect (1) our cash expenditures or future requirements for capital expenditures or contractual commitments; (2) changes in, or cash requirements for, our working capital needs; (3) the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt; (4) income taxes or the cash requirements for any tax payments; and (5) all of the costs associated with operating our business; |
| ● |
Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and Adjusted EBITDA from continuing operations does not reflect any cash requirements for such replacements; |
| ● |
While stock-based compensation is a component of cost of products sold and operating expenses, the impact on our consolidated financial statements compared to other companies can vary significantly due to such factors as assumed life of the stock-based awards and assumed volatility of our common stock; and |
| ● |
Other companies may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure. |
We compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA only on a supplemental basis. Neither current nor potential investors in our securities should rely on Adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of Adjusted EBITDA to net income (loss) attributable to Ultralife.
Adjusted EBITDA is calculated as follows for the periods presented:
| Three-month period ended |
||||||||
| March 31, |
March 31, |
|||||||
| 2022 |
2021 |
|||||||
| Net (loss) income attributable to Ultralife |
$ | (168 | ) | $ | 671 | |||
| Add: |
||||||||
| Interest expense |
134 | 56 | ||||||
| Income tax (benefit) provision |
(251 | ) | 217 | |||||
| Depreciation expense |
816 | 730 | ||||||
| Amortization of intangible assets |
328 | 154 | ||||||
| Stock-based compensation expense |
189 | 184 | ||||||
| Non-cash purchase accounting adjustments |
55 | - | ||||||
| Adjusted EBITDA |
$ | 1,103 | $ | 2,012 | ||||
Liquidity and Capital Resources
As of March 31, 2022, cash totaled $6,050 (including restricted cash of $82), a decrease of $2,363 as compared to $8,413 of cash held at December 31, 2021, primarily attributable to cash used in operations primarily caused by increases in inventory and accounts receivable.
During the three-month period ended March 31, 2022, we used $3,222 from our operations as compared to the generation of cash of $3,903 from operations for the three-month period ended March 31, 2021. The net cash used in the 2022 period was largely attributable to cash of $3,274 used to procure inventory to enhance our ability to service our backlog requested by customers to ship in 2022 amidst challenging supply conditions. The increase in inventory along with the timing of collections and disbursements resulted in net cash of $3,999 used for working capital. In addition to the increase in working capital, the use of cash from operating activities in the first quarter of 2022 reflects the net loss of $161, including purchase accounting adjustments of $55, and non-cash expenses totaling $938 for depreciation, amortization, stock-based compensation, and deferred taxes.
Cash used in investing activities for the three months ended March 31, 2022 was $371 for capital expenditures, reflecting investments in equipment for new products transitioning to high-volume manufacturing.
Net cash provided by financing activities for the three months ended March 31, 2022 was $1,223, consisting of draws from our credit facility for the purchase of certain critical raw materials requiring cash-in-advance payment terms by the vendors, partially offset by $333 of principle payments against our term loan balance and $7 of tax withholdings for stock awards, partially offset by proceeds of $113 from stock options exercises.
We continue to have significant U.S. net operating loss carryforwards available to utilize as an offset to future taxable income. See Note 7 to the Consolidated Financial Statements of this Form 10-Q for additional information.
Going forward, we expect positive operating cash flow and the availability under our Revolving Credit Facility will be sufficient to meet our general funding requirements for the foreseeable future.
To provide flexibility in accessing the capital market, the Company filed a shelf registration statement on Form S-3 on March 30, 2021, which was declared effective by the SEC on April 2, 2021. Under this registration statement, upon the filing of an appropriate supplemental prospectus, we may offer and sell certain of our securities from time to time in one or more offerings, at our discretion, of up to an aggregate offering price of $100 million. We intend to use the net proceeds resulting from any sales of our securities for general corporate purposes which may include, but are not limited to, potential acquisitions of complementary businesses or technologies, strategic capital expenditures to expand and protect our competitive position, and investments in the development of transformational, competitively-differentiated products for attractive growth markets.
Commitments
As of March 31, 2022, the Company had $12,430 outstanding borrowings on the Revolving Credit Facility and $9,667 on the Term Loan Facility. The Company was in full compliance with all covenants under the Credit Facilities as of March 31, 2022.
As of March 31, 2022, we had made commitments to purchase approximately $953 of production machinery and equipment.
Critical Accounting Policies
Management exercises judgment in making important decisions pertaining to choosing and applying accounting policies and methodologies in many areas. Not only are these decisions necessary to comply with GAAP, but they also reflect management’s view of the most appropriate manner in which to record and report our overall financial performance. All accounting policies are important, and all policies described in Note 1 (“Summary of Operations and Significant Accounting Policies”) to the Consolidated Financial Statements in our 2021 Annual Report on Form 10-K should be reviewed for a greater understanding of how our financial performance is recorded and reported.
During the first quarter of 2022, there were no significant changes in the manner in which our significant accounting policies were applied or in which related assumptions and estimates were developed.
Item 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our President and Chief Executive Officer (Principal Executive Officer) and our Chief Financial Officer and Treasurer (Principal Financial Officer) have evaluated our disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15(e)) as of the end of the period covered by this quarterly report. Based on this evaluation, our President and Chief Executive Officer and Chief Financial Officer and Treasurer concluded that our disclosure controls and procedures were effective as of such date.
Changes in Internal Control Over Financial Reporting
There has been no change in our internal control over financial reporting (as defined in Securities Exchange Act Rule 13a-15(f)) that occurred during the fiscal quarter covered by this quarterly report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 6. Exhibits
| Exhibit Index |
Exhibit Description |
Incorporated by Reference from |
||
| 31.1 |
Filed herewith |
|||
| 31.2 |
Filed herewith |
|||
| 32 |
Furnished herewith |
|||
| 101.INS |
Inline XBRL Instance Document |
Filed herewith |
||
| 101.SCH |
Inline XBRL Taxonomy Extension Schema Document |
Filed herewith |
||
| 101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
Filed herewith |
||
| 101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document |
Filed herewith |
||
| 101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
Filed herewith |
||
| 101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document |
Filed herewith |
||
| 104 |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
Filed herewith |
Attached as Exhibit 101 to this report are the following formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021, (ii) Consolidated Statements of Income and Comprehensive Income for the three months ended March 31, 2022 and 2021, (iii) Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021, (iv) Consolidated Statements of Changes in Shareholders’ Equity for the three months ended March 31, 2022 and 2021, and (v) Notes to Consolidated Financial Statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ULTRALIFE CORPORATION |
||||
| (Registrant) |
||||
| Date: April 28, 2022 |
By: | /s/ Michael D. Popielec |
||
| Michael D. Popielec |
||||
| President and Chief Executive Officer |
||||
| (Principal Executive Officer) |
||||
| Date: April 28, 2022 |
By: | /s/ Philip A. Fain |
||
| Philip A. Fain |
||||
| Chief Financial Officer and Treasurer |
||||
| (Principal Financial Officer and |
||||
| Principal Accounting Officer) |
Exhibit 31.1
I, Michael D. Popielec, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q of Ultralife Corporation; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
Date: April 28, 2022 |
By: |
/s/ Michael D. Popielec |
||
|
Michael D. Popielec |
||||
|
President and Chief Executive Officer |
Exhibit 31.2
I, Philip A. Fain, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q of Ultralife Corporation; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
Date: April 28, 2022 |
By: |
/s/ Philip A. Fain |
||
|
Philip A. Fain |
||||
|
Chief Financial Officer and Treasurer |
Exhibit 32
Section 1350 Certification
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), Michael D. Popielec and Philip A. Fain, the President and Chief Executive Officer and Chief Financial Officer and Treasurer, respectively, of Ultralife Corporation, certify that (i) the Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Ultralife Corporation.
A signed original of this written statement required by Section 906 has been provided to Ultralife Corporation and will be retained by Ultralife Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
|
Date: April 28, 2022 |
By: |
/s/ Michael D. Popielec |
||
|
Michael D. Popielec |
||||
|
President and Chief Executive Officer |
||||
|
Date: April 28, 2022 |
By: |
/s/ Philip A. Fain |
||
|
Philip A. Fain |
||||
|
Chief Financial Officer and Treasurer |